FBIO · XBRL financial data

Fortress Biotech financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	45,599	68,791	75,743	84,513	57,675	63,262
Cost of goods and services sold	14,594	32,084	30,775	26,660	20,879	20,924
Research and development	64,109	128,865	134,876	106,071	—	—
Selling, general and administrative	61,166	86,843	113,656	94,124	87,731	96,400
General and administrative	43,782	—	—	—	—	—
Operating income (loss)	(94,270)	(188,541)	(203,564)	(142,342)	(110,379)	(70,221)
Interest income	1,518	649	1,398	3,003	2,683	2,485
Interest expense	15,326	15,308	12,482	15,315	13,527	10,106
Other income (expense)	—	—	1,215	(3,403)	1,318	17,578
Income tax expense (benefit)	136	473	449	521	312	(620)
Net income (loss)	(46,526)	(64,703)	(86,575)	(60,637)	(45,997)	6,815
Earnings per share, basic‡ USD per share	—	(11.84)	(14.54)	(8.47)	(2.69)	(0.07)
Earnings per share, diluted‡ USD per share	—	(11.84)	(14.54)	(8.47)	(2.69)	(0.07)
Weighted average shares, basic‡ thousands of shares	—	5,449	5,928	8,111	20,784	27,902
Weighted average shares, diluted‡ thousands of shares	—	5,449	5,928	8,111	20,784	27,902

‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2023); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (FBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	233,351	305,744	178,266	80,927	57,263	79,381
Accounts receivable	19,349	23,112	28,208	15,222	10,231	29,783
Inventory	1,404	9,862	14,159	10,206	14,431	9,624
Prepaid and other current assets	6,723	7,066	9,661	10,500	7,110	4,895
Total current assets	261,571	346,462	230,432	117,022	90,371	123,841
Property and equipment, net	11,923	15,066	13,020	6,505	3,260	2,519
Right-of-use asset	20,487	19,005	19,991	16,990	13,861	12,302
Total assets	328,834	396,503	294,301	167,526	144,223	185,548
Accounts payable	11,412	47,429	57,244	34,810	31,636	14,238
Accrued liabilities	29,262	90,660	97,446	73,562	65,501	47,125
Total current liabilities	47,959	101,042	127,715	84,908	71,399	49,744
Lease liability, non-current	22,891	20,987	21,572	18,282	14,750	12,672
Total liabilities	131,835	170,626	244,276	165,939	145,867	123,365
Accumulated deficit	(482,760)	(547,463)	(634,233)	(694,870)	(740,867)	(734,052)
Total stockholders' equity	100,338	108,674	41,721	22,544	22,737	49,873
Total liabilities and equity	328,834	396,503	294,301	167,526	144,223	185,548
Common shares outstanding (cover page)‡ thousands of shares	6,328	6,766	7,370	15,093	27,909	31,364

‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2023); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (FBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(46,526)	(64,703)	(86,575)	(60,637)	(45,997)	6,815
Stock-based compensation	13,451	19,486	22,987	17,029	32,619	28,739
Net cash from operating activities	(83,682)	(116,540)	(179,401)	(128,225)	(80,191)	(65,777)
Purchases of property and equipment	1,926	4,566	2,715	63	0	—
Net cash from investing activities	(7,164)	40,514	(22,928)	(2,103)	(15,000)	10,121
Proceeds from issuing common stock	47,509	9,085	6,053	2,041	3,734	1,008
Share repurchases	70	—	—	—	—	—
Dividends paid	237	749	749	736	694	664
Net cash from financing activities	172,410	148,994	75,319	32,739	70,641	77,442
Net change in cash	81,564	72,968	(127,010)	(97,589)	(24,550)	21,786

† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.